$1.27
-0.05-3.79%
At close: -
$1.28
0.010.79%
After Hours: 4:20 PM EDT
Comments
Loading...
Pacific Biosciences Analyst Ratings and Price Targets | NASDAQ:PACB | Benzinga
Pacific Biosciences of California Inc has a consensus price target of $4.39 based on the ratings of 17 analysts. The high is $17 issued by Goldman Sachs on June 30, 2023. The low is $1.5 issued by Goldman Sachs on February 18, 2025. The 3 most-recent analyst ratings were released by Canaccord Genuity, Scotiabank, and Piper Sandler on April 10, 2025, March 25, 2025, and February 20, 2025, respectively. With an average price target of $2.33 between Canaccord Genuity, Scotiabank, and Piper Sandler, there's an implied 82.29% upside for Pacific Biosciences of California Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Scotiabank
Piper Sandler
Goldman Sachs
Stephens & Co.
1calculated from analyst ratings
Analyst Ratings for Pacific Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 134.38% | Canaccord Genuity | Kyle Mikson33% | $3 → $3 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | 56.25% | Scotiabank | Sung Ji Nam46% | $6 → $2 | Maintains | Sector Outperform | Get Alert |
| 02/20/2025 | Buy Now | 56.25% | Piper Sandler | David Westenberg59% | $2.5 → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 02/18/2025 | Buy Now | 17.19% | Goldman Sachs | Matthew Sykes65% | $1.75 → $1.5 | Maintains | Neutral | Get Alert |
| 02/18/2025 | Buy Now | 95.31% | Stephens & Co. | Mason Carrico39% | $2.5 → $2.5 | Reiterates | Overweight → Overweight | Get Alert |
| 02/14/2025 | Buy Now | 95.31% | Stephens & Co. | Mason Carrico39% | $2.5 → $2.5 | Reiterates | Overweight → Overweight | Get Alert |
| 01/23/2025 | Buy Now | 36.72% | Goldman Sachs | Matthew Sykes65% | $2.25 → $1.75 | Maintains | Neutral | Get Alert |
| 11/11/2024 | Buy Now | 56.25% | UBS | John Sourbeer30% | → $2 | Downgrade | Buy → Neutral | Get Alert |
| 11/11/2024 | Buy Now | 368.75% | Scotiabank | Sung Ji Nam46% | $7 → $6 | Maintains | Sector Outperform | Get Alert |
| 11/11/2024 | Buy Now | 95.31% | Piper Sandler | David Westenberg59% | $2 → $2.5 | Maintains | Neutral | Get Alert |
| 08/28/2024 | Buy Now | 446.88% | Scotiabank | Sung Ji Nam46% | $8 → $7 | Maintains | Sector Outperform | Get Alert |
| 08/13/2024 | Buy Now | 95.31% | Stephens & Co. | Mason Carrico39% | $3.5 → $2.5 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 56.25% | Morgan Stanley | Tejas Savant50% | $4 → $2 | Maintains | Equal-Weight | Get Alert |
| 08/08/2024 | Buy Now | 173.44% | Cantor Fitzgerald | Ross Osborn42% | $3.5 → $3.5 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 134.38% | Canaccord Genuity | Kyle Mikson33% | $3.5 → $3 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 212.5% | Jefferies | Tycho Peterson82% | → $4 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 212.5% | Morgan Stanley | Tejas Savant50% | $10 → $4 | Maintains | Equal-Weight | Get Alert |
| 05/13/2024 | Buy Now | 56.25% | Piper Sandler | David Westenberg59% | $6.5 → $2 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 56.25% | Barclays | Luke Sergott52% | $3 → $2 | Maintains | Equal-Weight | Get Alert |
| 04/22/2024 | Buy Now | — | JP Morgan | Rachel Vatnsdal60% | — | Downgrade | Overweight → Neutral | Get Alert |
| 04/19/2024 | Buy Now | 95.31% | Goldman Sachs | Matthew Sykes65% | $7 → $2.5 | Maintains | Neutral | Get Alert |
| 04/18/2024 | Buy Now | 95.31% | Bernstein | Eve Burstein44% | $9 → $2.5 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | 95.31% | Goldman Sachs | Matthew Sykes65% | $7 → $2.5 | Downgrade | Buy → Neutral | Get Alert |
| 04/18/2024 | Buy Now | 525% | Scotiabank | Sung Ji Nam46% | $15 → $8 | Maintains | Sector Outperform | Get Alert |
| 04/17/2024 | Buy Now | 95.31% | TD Cowen | Daniel Brennan47% | $12 → $2.5 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 134.38% | Barclays | Luke Sergott52% | $8 → $3 | Maintains | Equal-Weight | Get Alert |
| 04/10/2024 | Buy Now | 446.88% | Goldman Sachs | Matthew Sykes65% | $9 → $7 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | 681.25% | Canaccord Genuity | Kyle Mikson33% | $14 → $10 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 837.5% | UBS | John Sourbeer30% | $12.5 → $12 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 759.38% | Stephens & Co. | Mason Carrico39% | → $11 | Initiates | → Overweight | Get Alert |
| 12/14/2023 | Buy Now | — | Guggenheim | Subbu Nambi38% | — | Initiates | → Neutral | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel71% | — | Initiates | → Peer Perform | Get Alert |
| 11/17/2023 | Buy Now | 681.25% | UBS | John Sourbeer30% | $13 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 11/06/2023 | Buy Now | 525% | Piper Sandler | David Westenberg59% | $9 → $8 | Maintains | Neutral | Get Alert |
| 10/31/2023 | Buy Now | 1071.88% | Canaccord Genuity | Kyle Mikson33% | $17 → $15 | Maintains | Buy | Get Alert |
| 10/31/2023 | Buy Now | 759.38% | Cantor Fitzgerald | Ross Osborn42% | $14 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 10/24/2023 | Buy Now | 681.25% | Morgan Stanley | Tejas Savant50% | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 603.13% | Piper Sandler | David Westenberg59% | $13 → $9 | Maintains | Neutral | Get Alert |
| 09/29/2023 | Buy Now | 603.13% | Barclays | Luke Sergott52% | $14 → $9 | Maintains | Equal-Weight | Get Alert |
| 09/28/2023 | Buy Now | 759.38% | Bernstein | Eve Burstein44% | → $11 | Initiates | → Outperform | Get Alert |
| 09/26/2023 | Buy Now | 993.75% | Cantor Fitzgerald | Ross Osborn42% | → $14 | Reiterates | Neutral → Neutral | Get Alert |
| 08/22/2023 | Buy Now | 993.75% | Cantor Fitzgerald | Ross Osborn42% | → $14 | Reiterates | Neutral → Neutral | Get Alert |
| 08/04/2023 | Buy Now | 915.63% | Morgan Stanley | Tejas Savant50% | $13 → $13 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 915.63% | Morgan Stanley | Tejas Savant50% | $12 → $13 | Maintains | Equal-Weight | Get Alert |
| 06/30/2023 | Buy Now | 1228.13% | Goldman Sachs | — | → $17 | Initiates | → Buy | Get Alert |
| 06/05/2023 | Buy Now | 1228.13% | Canaccord Genuity | Kyle Mikson33% | $14 → $17 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 993.75% | Barclays | Luke Sergott52% | → $14 | Initiates | → Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 837.5% | Morgan Stanley | Tejas Savant50% | $10 → $12 | Maintains | Equal-Weight | Get Alert |
| 05/03/2023 | Buy Now | 1228.13% | TD Cowen | Daniel Brennan47% | $15 → $17 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | 915.63% | Cantor Fitzgerald | Ross Osborn42% | $12 → $13 | Maintains | Neutral | Get Alert |
| 03/31/2023 | Buy Now | 1071.88% | TD Cowen | Dan Brennan64% | $13 → $15 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/05/2023 | Buy Now | 837.5% | Scotiabank | Sung Ji Nam46% | → $12 | Initiates | → Sector Outperform | Get Alert |
| 11/16/2022 | Buy Now | 993.75% | Canaccord Genuity | Kyle Mikson33% | $12 → $14 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | 485.94% | Piper Sandler | David Westenberg59% | $6 → $7.5 | Maintains | Neutral | Get Alert |
| 05/16/2022 | Buy Now | 368.75% | Piper Sandler | David Westenberg59% | $13 → $6 | Maintains | Neutral | Get Alert |
| 05/06/2022 | Buy Now | 993.75% | Morgan Stanley | Tejas Savant50% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Pacific Biosciences (PACB) stock?
The latest price target for Pacific Biosciences (NASDAQ:PACB) was reported by Canaccord Genuity on April 10, 2025. The analyst firm set a price target for $3.00 expecting PACB to rise to within 12 months (a possible 134.38% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacific Biosciences (PACB)?
The latest analyst rating for Pacific Biosciences (NASDAQ:PACB) was provided by Canaccord Genuity, and Pacific Biosciences maintained their buy rating.
When was the last upgrade for Pacific Biosciences (PACB)?
The last upgrade for Pacific Biosciences of California Inc happened on November 17, 2023 when UBS raised their price target to $10. UBS previously had a neutral for Pacific Biosciences of California Inc.
When was the last downgrade for Pacific Biosciences (PACB)?
The last downgrade for Pacific Biosciences of California Inc happened on November 11, 2024 when UBS changed their price target from N/A to $2 for Pacific Biosciences of California Inc.
When is the next analyst rating going to be posted or updated for Pacific Biosciences (PACB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Pacific Biosciences (PACB) correct?
While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $3.00 to $3.00. The current price Pacific Biosciences (PACB) is trading at is $1.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.